CL2025003893A1 - Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides - Google Patents

Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides

Info

Publication number
CL2025003893A1
CL2025003893A1 CL2025003893A CL2025003893A CL2025003893A1 CL 2025003893 A1 CL2025003893 A1 CL 2025003893A1 CL 2025003893 A CL2025003893 A CL 2025003893A CL 2025003893 A CL2025003893 A CL 2025003893A CL 2025003893 A1 CL2025003893 A1 CL 2025003893A1
Authority
CL
Chile
Prior art keywords
monoclonal antibody
binds
types
amyloid fibrils
amyloid
Prior art date
Application number
CL2025003893A
Other languages
English (en)
Spanish (es)
Inventor
Brian Pepys Mark
Langley David
Jackson Jennifer
William Wade Jack
Christ Daniel
Henry Jake
Original Assignee
Immutrin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2308884.2A external-priority patent/GB202308884D0/en
Priority claimed from GBGB2308898.2A external-priority patent/GB202308898D0/en
Application filed by Immutrin Ltd filed Critical Immutrin Ltd
Publication of CL2025003893A1 publication Critical patent/CL2025003893A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hospice & Palliative Care (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CL2025003893A 2023-06-14 2025-12-11 Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides CL2025003893A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2308884.2A GB202308884D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies
GBGB2308898.2A GB202308898D0 (en) 2023-06-14 2023-06-14 Anti-fibril antibodies

Publications (1)

Publication Number Publication Date
CL2025003893A1 true CL2025003893A1 (es) 2026-01-30

Family

ID=91580895

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2025003893A CL2025003893A1 (es) 2023-06-14 2025-12-11 Anticuerpo monoclonal que se une a al menos 3 tipos de fibrillas amiloides

Country Status (8)

Country Link
EP (1) EP4727650A1 (fr)
KR (1) KR20260026033A (fr)
CN (1) CN121487964A (fr)
AU (1) AU2024304161A1 (fr)
CL (1) CL2025003893A1 (fr)
IL (1) IL325202A (fr)
MX (1) MX2025014924A (fr)
WO (1) WO2024256583A1 (fr)

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
WO1991000906A1 (fr) 1989-07-12 1991-01-24 Genetics Institute, Inc. Animaux chimeriques et transgeniques pouvant produire des anticorps humains
DE69133557D1 (de) 1990-08-29 2007-03-15 Pharming Intellectual Pty Bv Homologe rekombination in säugetier-zellen
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US6342220B1 (en) 1997-08-25 2002-01-29 Genentech, Inc. Agonist antibodies
US6475220B1 (en) 1999-10-15 2002-11-05 Whiteside Biomechanics, Inc. Spinal cable system
WO2015092077A1 (fr) * 2013-12-20 2015-06-25 Neurimmune Holding Ag Thérapie de l'amyloïdose de la transthyrétine (ttr) à base d'anticorps, et anticorps d'origine humaine afférents
CN106574258B (zh) * 2014-01-29 2021-03-30 Km生物医药股份公司 抗-运甲状腺素蛋白人源化抗体
CN111315213B (zh) * 2017-10-06 2023-09-12 普罗塞纳生物科学有限公司 抗甲状腺素运载蛋白抗体
EP4237005A4 (fr) * 2020-10-28 2024-10-09 Novo Nordisk A/S Anticorps anti-transthyrétine et méthodes d'utilisation associées

Also Published As

Publication number Publication date
EP4727650A1 (fr) 2026-04-22
KR20260026033A (ko) 2026-02-25
MX2025014924A (es) 2026-02-03
CN121487964A (zh) 2026-02-06
IL325202A (en) 2026-02-01
AU2024304161A1 (en) 2025-12-11
WO2024256583A1 (fr) 2024-12-19

Similar Documents

Publication Publication Date Title
DOP2021000264A (es) Fragmentos de unión al antígeno cd3 y composiciones que comprenden los mismos
CO2019012143A2 (es) Formulaciones estables de anticuerpos anti-ctla4 solos y en combinación con anticuerpos contra el receptor de muerte programada 1 (pd-1) y métodos para su uso
EP1425042A4 (fr) Inhibiteur de la voie du complement se fixant a c5 et a c5a sans empecher la formation de c5b
CL2022002670A1 (es) Anticuerpos contra amiloide-bcon piroglutamato y usos de estos (divisional solicitud 202102473).
SA523440043B1 (ar) أجسام مضادة ضد cd3 إبسيلون جديدة
EA202192260A1 (ru) Биомаркеры циклин-зависимой киназы 2 и их применение
BR112021008060A2 (pt) Polipeptídeo, anticorpo anti-ctla4 ou fragmento de anticorpo, imunoconjugado, composição farmacêutica, dose única de composição farmacêutica, método de tratar câncer, e, kit para diagnóstico ou tratamento
NO20082483L (no) Anvendelse av komplementreaksjonsveiinhibitorer for behandling av okulaere sykdommer
EA202191185A1 (ru) Способы ингибирования ангиогенеза у пациента
CY1120665T1 (el) Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους
JP2013231045A5 (fr)
PE20081264A1 (es) Anticuerpos agonistas anti-notch3
EA201290525A1 (ru) Новые антитела-антагонисты, их fab-фрагменты против gpvi и способы их применения
ES2617920T3 (es) Métodos para el tratamiento de la coagulación intravascular diseminada mediante la inhibición de la activación del complemento dependiente de MASP-2
PE20020574A1 (es) Anticuerpos humanizados que reconocen el peptido amiloideo beta
ECSP099656A (es) Anticuerpos ox40 antagonistas y su uso en el tratamiento de enfermedades inflamatorias y autoinmunes
GEAP202215170A (en) Humanized antibody for treating or preventing cognitive disorders, process for producing the same, and agent for treating or preventing cognitive disorders using the same
MX2022003911A (es) Anticuerpo, composicion farmaceutica y metodo.
AR069130A1 (es) Moleculas de enlace de la opsonina principal del complemento (c3b) y metodos para modular el componente de complemento
AR108717A1 (es) Anticuerpos antifactor de la coagulación xi
PH12021550244A1 (en) Anti-btla antibody
MX2023002496A (es) Anticuerpo que se une al factor de crecimiento endotelial vascular a (vegf-a) y a la angiopoyetina 2 (ang2) y metodos de uso.
AR128031A1 (es) Anticuerpos agonistas anti-ltbr y anticuerpos biespecíficos que los comprenden
MX2022005949A (es) Anticuerpos anti-ror-2 y metodos de uso.
CL2023003047A1 (es) Anticuerpo anti componente del complemento 1s (c1s)